Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Biotherapeutics, Inc.”

156 pharma patents match "Biotherapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 156
Index total 30,257
Page 1 / 7

Quick answer

This filtered view shows 156 pharmaceutical patents matching "Biotherapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

156 results for “Biotherapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 12390453

    Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  2. US 12383572

    Administration of an anti-activin-a compound to a subject

    Atara Biotherapeutics, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  3. US 12343380

    Expansion of TILs utilizing AKT pathways inhibitors

    Iovance Biotherapeutics, Inc. · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  4. US 12336983

    Inhibition of crystal growth of roflumilast

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  5. US 12329751

    Topical roflumilast formulation having antifungal properties

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  6. US 12325750

    Anti-Dectin-2 antibodies and methods of using

    Bolt Biotherapeutics, Inc. · Granted Jun 10, 2025 · Expires Jun 5, 2045

    granted
  7. US 12310956

    Topical roflumilast formulation having improved delivery and plasma half-life

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted May 27, 2025 · Expires May 22, 2045

    granted
  8. US 12280140

    Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  9. US 12257242

    Inhibition of crystal growth of roflumilast

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  10. US 12233075

    Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

    Iovance Biotherapeutics, Inc. · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted
  11. US 12230379

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  12. US 12226434

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  13. US 12230378

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  14. US 12220409

    Roflumilast formulations with an improved pharmacokinetic profile

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  15. US 12194061

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jan 14, 2025 · Expires Jan 9, 2045

    granted
  16. US 12188048

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  17. US 12170134

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Dec 17, 2024 · Expires Dec 12, 2044

    granted
  18. US 12161643

    Stable formulations of SHR0302

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  19. US 12159700

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted
  20. US 12144802

    Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  21. US 12121541

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  22. US 12104172

    Processes for generating TIL products enriched for tumor antigen-specific t-cells

    Iovance Biotherapeutics, Inc. · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  23. US 12083122

    Laureth-4 containing topical formulations

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  24. US 12053481

    Compositions and methods for deep dermal drug delivery

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted